Literature DB >> 759067

Furosemide-induced adverse reactions in cirrhosis of the liver.

C A Naranjo, E Pontigo, C Valdenegro, G González, I Ruiz, U Busto.   

Abstract

Furosemide is frequently used for ascites and causes adverse reactions (AR). In an intensive prospective drug monitoring study of 1,920 patients, 172 (8.9%) had cirrhosis of the liver and received furosemide. Mean age was 53 years, and 66.3% were male; and 87% had alcoholic cirrhosis. Eighty-eight (51.2%) had 221 events that by consensus of the monitoring team and attending physicians were either definitely of probably related to furosemide. No AR was fatal but 24% of patients had severe reactions. Almost all reactions were dose-related (96%). The most common were electrolyte disturbances (23.3% of patients) and volume depletion (14%). Furosemide-induced coma occurred in 20 (11.6%) patients and was more frequent in patients with prior hepatic encephalopathy (p less than 0.0005). Higher total doses (p less than 0.001), hyerbilirubinemia (p less than 0.05), prolonged prothrombin time (p less than 0.02), and longer hospital stay (p less than 0.001) were associated with higher frequencies of AR to furosemide. The frequency of hypokalemia did not decrease when potassium chloride or potassium-sparing diuretics were added to furosemide therapy. Frequdncy of AR did not correlate with age, sex, renal impairment, serum albumin, transaminase, or alkaline phosphatase.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 759067     DOI: 10.1002/cpt1979252154

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture.

Authors:  H Ring-Larsen; J H Henriksen; C Wilken; J Clausen; H Pals; N J Christensen
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-24

2.  A pharmacovigilance study on patients of bronchial asthma in a teaching hospital.

Authors:  A N Jamali; M Aqil; M S Alam; K K Pillai; P Kapur
Journal:  J Pharm Bioallied Sci       Date:  2010-10

3.  An intensive drug monitoring study suggesting possible clinical irrelevance of impaired drug disposition in liver disease.

Authors:  C A Naranjo; U Busto; E Janecek; I Ruiz; C A Roach; K Kaplan
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

4.  Pharmacokinetics of furosemide in patients with hepatic cirrhosis.

Authors:  G González; A Arancibia; M I Rivas; P Caro; C Antezana
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide.

Authors:  E Keller; G Hoppe-Seyler; R Mumm; P Schollmeyer
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Combined use of water immersion and frusemide in treatment of resistant ascites in liver cirrhosis.

Authors:  F Fawthrop; J P O'Hare; N Millar; C F Weston; A E Read
Journal:  J R Soc Med       Date:  1987-12       Impact factor: 18.000

Review 7.  Drug administration in chronic liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.228

8.  Successful treatment of refractory edema with traditional herbal medicine: A case report.

Authors:  Gayoung Lee; Jung-Hyo Cho; Chang-Gue Son; Namhun Lee
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.